share_log

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More

未來一周在生物技術 (6 月 5-11): Adcom 測試諾瓦克斯, ASCO 演示, 恩佐生化收益和更多
Benzinga Real-time News ·  2022/06/06 04:10
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
生物科技股與大盤一起逆轉走勢，截至6月3日的一週收盤走低。因此，該行業的精益運行得到了延長。
Genocea Biosciences, Inc. (NASDAQ:GNCA), which announced on May 24 plans to wind down of operations, continued to see weakness, ending the week down over 66%. The company is awaiting delisting of its stock from Nasdaq.
Genocea生物科學公司納斯達克(Sequoia Capital：GNCA)5月24日宣佈計劃逐步關閉業務，繼續表現疲軟，本週收盤時跌幅超過66%。該公司正在等待其股票從納斯達克退市。
Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) shares also came under intense selling pressure after it announced the Food and Drug Administration's decision to issue a refusal-to-file letter for its Arginase 1 deficiency treatment candidate.
Aeglea BioTreateutics公司納斯達克(Standard Chartered Bank：AGLE)宣佈美國食品和藥物管理局(FDA)決定拒絕為其精氨酸酵素1缺乏症候選藥物出具拒絕備案函後，其股價也面臨巨大的拋售壓力。
The week witnessed some activity on the...
這一週見證了並...
登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論